Loading…
Based on limited metadata, this warning letter from the FDA issued on October 3, 2019, was directed at Bingbing Pharmaceutical Co., Ltd regarding drug products. While the specific subject line and detailed violation count are unavailable, the letter indicates regulatory concerns related to the company's pharmaceutical manufacturing or distribution practices. Without access to the full warning letter text, the precise nature of the violations and specific regulatory deficiencies cannot be determined from this metadata alone.